INDIANAPOLIS (AP) – Drugmakers Eli Lilly and Co. and Boehringer Ingelheim said on August 25 that European regulators have approved their type 2 diabetes treatment Trajenta.
The drug, also known as linagliptin, is sold in the United States under the trade name Tradjenta. Lilly and Boehringer said the European Commission granted marketing authorization for 5-milligram tablets to be used alone or in combination with other treatments. Lilly and Boehringer entered an agreement earlier this year to develop and sell up to five drugs, and Tradjenta is the first of those products. In May, the U.S. Food and Drug Administration approved it to be used as a stand-alone treatment or in combination with other diabetes drugs.
The Associated Press
Filed Under: Drug Discovery
